DOCSLIB.ORG

Minutes of the 575Thmeeting Ofthe State

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Minutes of the 575Thmeeting Ofthe State Minutes of the 575th meeting ofthe State Level Expert Appraisal Committee(SEAC) held on 17/12/2019 at Committee Room, Gujarat Pollution Control Board, Sector 10A,Gandhinagar. The 575th meeting of the State Level Expert Appraisal Committee (SEAC) was held on 17 th December 2019 at Committee Room, Gujarat Pollution Control Board, Sector 10A, Gandhinagar. Following members attended the meeting: 1. Dr. Dinesh Misra, Chairman, SEAC 2. Shri S. C. Srivastav, Vice Chairman, SEAC 3. Shri V. N. Patel, Member, SEAC 4. Shri. R. J. Shah, Member, SEAC 5. Shri Rajesh. I. Shah, Member, SEAC 6. Shri A. K. Muley, Member, SEAC The regular agenda of Appraisal, Screening & Scoping/ToR – reconsideration, EC – Amendment, EC – Corrigendum cases were taken up. The Committee considered the applications made by project proponents, additional details submitted as required by the SEAC/SEIAA and details furnished in the Form-1, PFR, EIA- EMP reports. Proposal No. Name and Address of the Unit Remarks 6 SIA/GJ/IND2/45092/2019 M/s. Krufren Pharma Appraisal Plot No: C/251, GIDC Saykha, Vagra, Bharuch. Category of the unit : 5(f) Project status: Expansion • Project proponent (PP) submitted online application vide no. SIA/GJ/IND2/45092/2019dated 13/11/2019 for obtaining Environmental Clearance. • SEIAA issued TOR to PP vide their letter dated 24/05/2019. • Project proponent has submitted EIA Report prepared by Aqua Air Environmental Engineers Pvt Ltd, Ahmedabad based on the TOR issued by SEIAA. • This is an expansion project for manufacturing of synthetic organic chemical as tabulated below. Sr. Name of the Products CAS no. /CI no. Quantity End -use of the products No. MT/Month 1 Nabivilol 152520-56-4 1.0 Beta-Blocker 2 Zonisamide 68291-97-4 10.0 Anti Depression 3 Fluconazole 86386-73-4 10.0 Antifungal Medication 575 th meeting of SEAC-Gujarat, dated 17.12.2019 Page 1 of 178 4 Loratadine 79794-75-5 1.0 Anti Depression 5 Glimepride 93479-97-1 1.0 Anti Diabetic Amiodarone 6 1951-25-3 10.0 Irregular Heartbeats Hydrochloride 7 Cilostazol 73963-72-1 10.0 Intermittent Claudication 8 Apripitant 170729-80-3 10.0 Antiemetic Sevelamer 9 152751-57-0 10.0 A Noncalcemic Phosphate Binder Hydrochloride Nicardipine 10 54527-84-3 1.0 Calcium Channel Blockers. Hydrochloride 11 Amlodipine Besilate 111470-99-6 10.0 Calcium Channel Blockers. 12 Glibenclamide 10238-21-8 10.0 Anti Diabetic 13 Desloratadine 100643-71-8 1.0 Antihistamine Venlaflaxine 14 99300-78-4. 10.0 Antidepressant Hydrochloride 15 Telmisartan 144701-48-4 10.0 Anti Hypertension 16 Pregabalin 148553-50-8 10.0 Anxiety Disorders 17 Febuxostat 144060-53-7 10.0 Hyperuricemia. 18 Vildagliptin 274901-16-5 10.0 Anti Diabetic 19 Valsartan 137862-53-4 10.0 Anti Hypertensive 20 Topiramate 97240-79-4. 1.0 Antiepileptic 21 Ropivacine 132112-35-7 1.0 Local Anesthetic 22 Pedotimode 121808-62-6 1.0 Anti Neoplastic -- 23 R&D 1.0 For R & D Purpose Total 149 • The project falls under Category B of project activity 5(f) as per the schedule of EIA Notification 2006. 575 th meeting of SEAC-Gujarat, dated 17.12.2019 Page 2 of 178 • PP was called for presentation in the SEAC meeting dated 17/12/2019. • Salient features of the project are as under: Sr. no. Particulars Details A A Total cost of Proposed Project 4.0 Crores (Rs. in Crores): ii EMP details (Capital cost & Recurring cost) Brief details of EMP COMPONENT CAPITAL COST OF EMP RECURRING COST OF EMP (per (2019-20) Month) Cost Rs. 234.4 Lakhs Rs. 29.71 Lakhs Bifurcation of EMP Cost Sr. Unit Installed Capital Operating Maintenance Total No Capacity Cost Cost Cost Recurring (KLD) (Rs. in (Lacs/Month) (Lacs/Month) Cost Lakhs ) (Lacs/Month) 1 Effluent 42.05 KLD 200.0 18.73 0.35 19.08 Treatment Plant 2. APCM -- 11.0 -- 0.1 0.1 3. Hazardous -- 8.75 10.36 -- 10.36 Waste (Expense) 4. AWH -- 10.0 -- 0.125 0.125 Monitoring Cost 5. Greenbelt -- 4.65 -- 0.041 0.041 Total 234.4 29.09 0.616 29.706 Iii CER details (As per MoEF&CC OM dated 01/05/2018) As per OM no. 22-65/2017 on dated 01/05/2018 regarding “Corporate Environment Responsibility” (CER), greenfield projects have to contribute 2% of the Additional Capital Investment, the company 575 th meeting of SEAC-Gujarat, dated 17.12.2019 Page 3 of 178 will contribute Rs. 8.0 Lakhs as funds for CER activities Component As per Norms Allocation CER Rs. 8.0 Lakhs (2 %) Rs. 8.0 Lakhs (2 %) Activities to be carried out under CER: CER Activities Fund (Rs.) Provision & Installation of Water Cooler at Saykha Village 4,00,000 Provision & Installation of Water Cooler at Argama Village 4,00,000 Total 8,00,000/- B Total Plot area ( sq. meter) 4000 Sq. m. Green belt area 1200.0 Sq. m. ( sq. meter) C Employment generation 30 D Water i Source of Water Supply GIDC Water Supply (GIDC Bore well, Surface water, Tanker supply etc...) Status of permission from the concern authority. GIDC/DEE/(WS)/BRH/561 ii Water consumption (KLD) Category Quantity Remarks KLD (A) Domestic 2.0 (B) Gardening 1.5 (C) Industrial Process 28.0 Washing 2.0 Boiler 15.0 Cooling 5.0 Scrubber 2.0 R&D 0.026 Industrial Total 52.026 Total (A + B + C) 55.526 1) Total water requirement for the project: 55.526 KLD 2) Quantity to be recycled : 34 KLD 3) Total fresh water requirement: 21.526 KLD 575 th meeting of SEAC-Gujarat, dated 17.12.2019 Page 4 of 178 iii Waste water generation (KLD) - Category Waste water Remarks KLD (A) Domestic 1.5 (B) Industrial Process 33 Low COD & TDS: 23 KLD High COD & TDS: 10 KLD Washing 1.5 Boiler 1.5 Cooling 0.5 Scrubber 2.8 Reuse and sell under rule-9 permission (C) R&D 0.025 Total Industrial 39.325 waste water Total [A + B + C] 40.825 iv Treatment facility within premises with capacity [In-house ETP (Primary, Secondary, Tertiary), MEE, Stripper, Spray Dryer, STP etc. ETP (Primary, Secondary, Tertiary) & RO: 26.525 KLD MEE + Solvent Stripper : 15.525 KLD Treatment scheme including segregation at source. Low COD & TDS effluent from Process, Boiler, Cooling and Washing will be treated in ETP (Primary, Secondary, Tertiary & RO treatment. High COD & TDS effluent from process will be treated in-house MEE. Note: (In case of CETP discharge) : Management of waste water keeping in view direction under section 18 (1) (b) of the Water (Prevention and Control of Pollution) act, 1974 issued by CPCB regarding compliance of CETP . Not Applicable Brief note on adequacy of ZLD (In case of Zero Liquid Discharge): Total water requirement will be 55.526 KLD. Total reuse water will be 34.0 KLD from RO 575 th meeting of SEAC-Gujarat, dated 17.12.2019 Page 5 of 178 Permeate and MEE Condensate. Hence approximately 61.0% treated water will be reuse. v Mode of Disposal & Final meeting point Domestic: Disposal through soak pit/ septic tank Industrial: For Low COD & TDS: ETP consisting of Primary, Secondary, Tertiary & RO treatment. Treated effluent will be reuse. For High COD & TDS: ETP consisting of Primary treatment followed by MEE+ Solvent Stripper treatment. MEE condensate will be reuse. vi In case of Common facility (CF) like CETP, Common Spray dryer, Common MEE etc. Name of CF NA Membership of Common facility (CF) (For waste water treatment) Ref No.: BEIL/ANK/2019, dated 18/03/2019 vii Simplified water balance diagram with reuse / recycle of waste water viii Reuse/Recycle details (KLD) Total reuse: 0 KLD 575 th meeting of SEAC-Gujarat, dated 17.12.2019 Page 6 of 178 Source of waste water for Application area with Characteristics of waste water to be reuse with quantity in KLD quantity in KLD (Where reused (COD, BOD, TDS etc.) (From where it is coming) it is used) RO Permeate: 21.0 KLD Process: 21.0 KLD COD: 80 mg/l BOD: 25 mg/l TDS: 200 mg/l MEE Condensate: 13.0 KLD Boiler: 13.0 KLD COD: 150 mg/l BOD: 50 mg/l TDS: 500 mg/l E Air i Flue gas emission details No. of Boilers/TFH/Furnaces/DG sets etc. with capacities viz. TPH, Kcal/hr, MT/hr, KVA etc. -Proposed Source of Air Pollution Stack Quantity of Type of Sr. emission Control Height Type of Fuel Fuel emissions i.e. no. With Measures (meter) MT/Day Air Pollutants Capacity (APCM) SPM Multi Cyclone Briquettes of Boiler (2.0 3/2/2000 SO 2 Separator with 1 30 Biocoal/Coal/Nat TPH) SCM /Day NO x Bag Filter + ural Gas water Scrubber SPM Multi Cyclone Thermo Briquettes of SO 2 Separator with 3/2/2000 2 Pack (1.0 30 Biocoal/Coal/Nat NO x Bag Filter + SCM /Day lakhs kcal/hr) ural Gas Water Scrubber SPM D. G Set Adequate stack 3 11 HSD 0.05 SO 2 (100 KVA) Height NO x ii Process gas emission details i.e. Type of pollutant gases (SO 2, HCl, NH 3, Cl 2, NO x etc.) - Specific Source of Air Pollution Control Sr. emission Type of Stack/Vent Measures no. (Name of the emission Height (meter) (APCM) Product &Process) 575 th meeting of SEAC-Gujarat, dated 17.12.2019 Page 7 of 178 Process Vent 1 (Source: Loratadine HCl 11 Two stage Water scrubber Process) Process Vent 2 (Source: Loratadine SO 2 11 Two stage Alkali scrubber Process) Process Vent 3 (Source: Topiramate NH 3 11 Two Stage Acid Scrubber Process) iii Fugitive emission details with its mitigation measures: As below: Following measures will be adopted to prevent and control fugitive emissions: 1.
Load more

Recommended publications
  • Research Article RP-HPLC Method for Determination of Several Nsaids and Their Combination Drugs
    Hindawi Publishing Corporation Chromatography Research International Volume 2013, Article ID 242868, 13 pages http://dx.doi.org/10.1155/2013/242868 Research Article RP-HPLC Method for Determination of Several NSAIDs and Their Combination Drugs Prinesh N. Patel, Gananadhamu Samanthula, Vishalkumar Shrigod, Sudipkumar C. Modh, and Jainishkumar R. Chaudhari Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Balanagar, Hyderabad, Andhra Pradesh 500037, India Correspondence should be addressed to Gananadhamu Samanthula; [email protected] Received 29 June 2013; Accepted 13 October 2013 Academic Editor: Andrew Shalliker Copyright © 2013 Prinesh N. Patel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. An RP-HPLC method for simultaneous determination of 9 NSAIDs (paracetamol, salicylic acid, ibuprofen, naproxen, aceclofenac, diclofenac, ketorolac, etoricoxib, and aspirin) and their commonly prescribed combination drugs (thiocolchicoside, moxifloxacin, clopidogrel, chlorpheniramine maleate, dextromethorphan, and domperidone) was established. The separation was performed on ∘ Kromasil C18 (250 × 4.6 mm, 5 m) at 35 C using 15 mM phosphate buffer pH 3.25 and acetonitrile with gradient elution ata flow rate of 1.1 mL/min. The detection was performed by a diode array detector (DAD) at 230 nm with total run time of 30min. 2 Calibration curves were linear with correlation coefficients of determinationr ( ) > 0.999. Limit of detection (LOD) and Limit of quantification (LOQ) ranged from 0.04 to 0.97 g/mL and from 0.64 to 3.24 g/mL, respectively.
    [Show full text]
  • 01012100 Pure-Bred Horses 0 0 0 0 0 01012900 Lives Horses, Except
    AR BR UY Mercosu PY applied NCM Description applied applied applied r Final Comments tariff tariff tariff tariff Offer 01012100 Pure-bred horses 0 0 0 0 0 01012900 Lives horses, except pure-bred breeding 2 2 2 2 0 01013000 Asses, pure-bred breeding 4 4 4 4 4 01019000 Asses, except pure-bred breeding 4 4 4 4 4 01022110 Purebred breeding cattle, pregnant or lactating 0 0 0 0 0 01022190 Other pure-bred cattle, for breeding 0 0 0 0 0 Other bovine animals for breeding,pregnant or 01022911 lactating 2 2 2 2 0 01022919 Other bovine animals for breeding 2 2 2 2 4 01022990 Other live catlle 2 2 2 2 0 01023110 Pure-bred breeding buffalo, pregnant or lactating 0 0 0 0 0 01023190 Other pure-bred breeding buffalo 0 0 0 0 0 Other buffalo for breeding, ex. pure-bred or 01023911 pregnant 2 2 2 2 0 Other buffalo for breeding, except pure-bred 01023919 breeding 2 2 2 2 4 01023990 Other buffalos 2 2 2 2 0 01029000 Other live animals of bovine species 0 0 0 0 0 01031000 Pure-bred breedig swines 0 0 0 0 0 01039100 Other live swine, weighing less than 50 kg 2 2 2 2 0 01039200 Other live swine, weighing 50 kg or more 2 2 2 2 0 01041011 Pure-bred breeding, pregnant or lactating, sheep 0 0 0 0 0 01041019 Other pure-bred breeding sheep 0 0 0 0 0 01041090 Others live sheep 2 2 2 2 0 01042010 Pure-bred breeding goats 0 0 0 0 0 01042090 Other live goats 2 2 2 2 0 Fowls spec.gallus domestic.w<=185g pure-bred 01051110 breeding 0 0 0 0 0 Oth.live fowls spec.gall.domest.weig.not more than 01051190 185g 2 2 2 2 0 01051200 Live turkeys, weighing not more than 185g 2 2
    [Show full text]
  • Comparative Study of the Efficacy of Flunixin, Ketoprofen and Phenylbutazone in Delman Horses with Mild Colic
    Sys Rev Pharm 2020; 11(5): 464 468 A multifaceted review journal in the field of pharmacy E-ISSN 0976-2779 P-ISSN 0975-8453 Comparative Study of the Efficacy of Flunixin, Ketoprofen and Phenylbutazone in Delman Horses with Mild Colic Agus Purnomo1, Arya Pradana Wicaksono2, Dodit Hendrawan2, Muhammad Thohawi Elziyad Purnama3* 1Department of Veterinary Surgery and Radiology, Faculty of Veterinary Medicine, Universitas Gadjah Mada, DI Yogyakarta, 55281, Indonesia 2Postgraduate Studies, Faculty of Veterinary Medicine, Universitas Airlangga, Surabaya, 60115, Indonesia 3Department of Veterinary Anatomy, Faculty of Veterinary Medicine, Universitas Airlangga, Surabaya, 60115, Indonesia *Corresponding author E-mail: [email protected] Article History: Submitted: 26.02.2020 Revised: 16.04.2020 Accepted: 21.05.2020 ABSTRACT This study aimed to evaluate the efficacy of flunixin, ketoprofen and multiple range test. The results showed a significant alleviation in all phenylbutazone on serum biochemistry, plasma catecholamines and observed variables on Day 13, although the use of various NSAIDs serum cortisol in Delman horses with mild colic. During the study showed no significant difference. period, 32 horses were evaluated due to mild colic. Flunixin, Keywords: serum biochemical, catecholamine, cortisol, colic, NSAIDs ketoprofen, and phenylbutazone were administered intravenously at Correspondence: the recommended dose rates of 1.0; 2.2 and 4.4 mg/kg, respectively. Muhammad Thohawi Elziyad Purnama Administration of the NSAIDs commenced on Day 1 and continued Department of Veterinary Anatomy, Faculty of Veterinary Medicine, every 12 h for 12 days. Blood samples collected between days 2, 5, 9 Universitas Airlangga, Surabaya, 60115, Indonesia and 13 to evaluate AST, ALP, GGT, creatinine, urea, epinephrine, E-mail: [email protected] norepinephrine, and cortisol level.
    [Show full text]
  • Nicolau Syndrome: a Review of Case Studies, Pharm Sci
    The following manuscript was accepted for publication in Pharmaceutical Sciences. It is assigned to an issue after technical editing, formatting for publication and author proofing. Citation: Mojarrad P, Mollazadeh H, Barikbin B, Oghazian MB. Nicolau syndrome: a review of case studies, Pharm Sci. 2021, doi: 10.34172/PS.2021.32 Nicolau syndrome: a review of case studies Paria Mojarrad1, Hamid Mollazadeh2,3, Behnaz Barikbin1, Mohammad Bagher Oghazian4,1* 1 Clinical Research Development Unit, Imam Hasan Hospital, North Khorasan University of Medical Sciences, Bojnurd, Iran 2 Department of Physiology and Pharmacology, North Khorasan University of Medical Sciences, Bojnurd, Iran 3 Natural Product and Medicinal Plant Research Center, North Khorasan University of Medical Sciences, Bojnurd, Iran 4 Department of Internal Medicine, Faculty of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran *Corresponding author: Mohammad Bagher Oghazian, Tel: +989151087370.Email: [email protected] Pharmaceutical Sciences (Indexed in ISI and Scopus) https://ps.tbzmed.ac.ir Abstract Nicolau syndrome, although it is quite rare, often occurs following intramuscular injections of different medications, especially diclofenac and penicillins. Accordingly, its symptoms usually begin with severe pain during injection, leading to ulceration and necrosis of the local tissue over time. Immediate diagnosis and treatment in the case of this syndrome, are of great importance. There are no established criteria for Nicolau's diagnosis, and preferably, these can be achieved by examining the patient's symptoms and eliminating differential diagnoses. The proposed treatments are primarily symptomatic therapy and measures such as fasciotomy, debridement, and plastic surgery provided in the affected area. The exact cause of this syndrome has not been determined yet.
    [Show full text]
  • 18 Analgesics Anti-Inflammatory Drugs and Antipyretics the Dosage of Alfentanil Used Depends on Whether the 2
    18 Analgesics Anti-inflammatory Drugs and Antipyretics The dosage of alfentanil used depends on whether the 2. Virkkilä M, et al. Pharmacokinetics and effects of i.m. alfentanil minutes). However, some considered that there was no over- patient has spontaneous respiration or assisted ventila- as premedication for day-case ophthalmic surgery in elderly pa- all advantage of epidural over intravenous alfentanil either as tients. Br J Anaesth 1993; 71: 507–11. patient-controlled analgesia2 or by continuous infusion.3 tion and on the expected duration of anaesthesia. Doses 3. Hughes DA, Hill DA. Intrathecal alfentanil with and without bupivacaine for analgesia in labour. Anaesthesia 2000; 55: 1. Chrubasik J, et al. Relative analgesic potency of epidural fenta- are adjusted according to the needs of the patient. Chil- 1116–21. nyl, alfentanil, and morphine in treatment of postoperative pain. dren may require higher or more frequent doses than Anesthesiology 1988; 68: 929–33. Administration in children. Alfentanil is licensed in the UK 2. Chauvin M, et al. Equivalence of postoperative analgesia with adults, whereas the elderly or debilitated patients may for use in ventilated children during surgical procedures as an patient-controlled intravenous or epidural alfentanil. Anesth An- require lower or less frequent doses. Obese patients analgesic and adjunct to general anaesthetics or as a primary an- alg 1993; 76: 1251–8. may require doses based on their ideal (lean) body- aesthetic. When used as an adjunct in the maintenance of gen- 3. van den Nieuwenhuyzen MCO, et al. Epidural vs intravenous infusion of alfentanil in the management of postoperative pain weight.
    [Show full text]
  • Non Steroidal Anti-Inflammatory Drugs
    Non Steroidal Anti‐inflammatory Drugs (NSAIDs) 4 signs of inflammation • Redness ‐ due to local vessel dilatation • Heat ‐ due to local vessel dilatation • Swelling – due to influx of plasma proteins and phagocytic cells into the tissue spaces • Pain – due to local release of enzymes and increased tissue pressure NSAIDs • Cause relief of pain ‐. analgesic • Suppress the signs and symptoms of inflammation. • Exert antipyretic action. • Useful in pain related to inflammation. Esp for superficial/integumental pain . Classification of NSAIDs • Salicylates: aspirin, Sodium salicylate & diflunisal. • Propionic acid derivatives: ibuprofen, ketoprofen, naproxen. • Aryl acetic acid derivatives: diclofenac, ketorolac • Indole derivatives: indomethacin, sulindac • Alkanones: Nabumetone. • Oxicams: piroxicam, tenoxicam Classification of NSAIDs ….. • Anthranilic acid derivatives (fenamates): mefenamic acid and flufenamic acid. • Pyrazolone derivatives: phenylbutazone, oxyphenbutazone, azapropazone (apazone) & dipyrone (novalgine). • Aniline derivatives (analgesic only): paracetamol. Clinical Classif. • Non selective Irreversible COX inhibitors • Non slective Reversible COX inhibitors • Preferential COX 2 inhibitors • 10‐20 fold cox 2 selective • meloxicam, etodolac, nabumetone • Selective COX 2 inhibitors • > 50 fold COX ‐2 selective • Celecoxib, Etoricoxib, Rofecoxib, Valdecoxib • COX 3 Inhibitor? PCM Cyclooxygenase‐1 (COX‐1): -constitutively expressed in wide variety of cells all over the body. -"housekeeping enzyme" -ex. gastric cytoprotection, hemostasis Cyclooxygenase‐2 (COX‐2): -inducible enzyme -dramatically up-regulated during inflammation (10-18X) -constitutive : maintains renal blood flow and renal electrolyte homeostasis Salicylates Acetyl salicylic acid (aspirin). Kinetics: • Well absorbed from the stomach, more from upper small intestine. • Distributed all over the body, 50‐80% bound to plasma protein (albumin). • Metabolized to acetic acid and salicylates (active metabolite). • Salicylate is conjugated with glucuronic acid and glycine. • Excreted by the kidney.
    [Show full text]
  • Discovery of Novel Pyridazine-Based Cyclooxygenase-2 Inhibitors with a Promising Gastric Safety Profile
    molecules Article Discovery of Novel Pyridazine-Based Cyclooxygenase-2 Inhibitors with a Promising Gastric Safety Profile Abida Khan 1,* , Anupama Diwan 1, Hamdy Kh. Thabet 2, Mohd Imran 3 and Md. Afroz Bakht 4 1 School of Pharmaceutical Sciences, Apeejay Stya University, Sohna - Palwal Road, Sohna 122103, India; [email protected] 2 Department of Chemistry, Faculty of Arts and Science, Northern Border University, Rafha 91911, Saudi Arabia; [email protected] 3 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Northern Border University, Rafha 91911, Saudi Arabia; [email protected] 4 Department of Chemistry, College of Science and Humanities, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia; [email protected] * Correspondence: [email protected]; Tel.: +91-8053027613 Received: 25 March 2020; Accepted: 21 April 2020; Published: 25 April 2020 Abstract: Cyclooxygenase-2 (COX-2) is implicated in the development of chronic inflammatory diseases. Recently, pyridazine derivatives have emerged as a novel prototype to develop COX-2 inhibitors. Accordingly, some pyridazine-based COX-2 inhibitors are reported herein. The reaction of aldehyde 3 and different hydrazines yielded the corresponding hydrazones. The hydrazones were further derivatized to the title compounds, which were assessed for COX-1 and COX-2 inhibitory action, gastric ulcerogenic effects, and lipid peroxidation properties. Molecular docking studies and determination of the physicochemical parameters were also carried out. The allocated structures of the reported compounds were coherent with their spectroscopic data. The compounds 9a (IC50 = 15.50 nM, 114.77%), 9b (IC50 = 17.50 nM, 101.65%), 12 (IC50 = 17.10 nM, 104.03%), 16b (IC50 = 16.90 nM, 105.26%), and 17 (IC50 = 17.70 nM, 100.5%) displayed better COX-2 inhibition than celecoxib (IC50 = 17.79 nM, 100%).
    [Show full text]
  • ANNEXURE Ii- Consolidated List of Unapproved List Licenced
    Fixed dose combinations – declared unapproved by Drug Controller General of India Sl No Name of fixed dose combinations 1. 5 - bromosalicyl - 4 - chloranilide + Salicylic acid 2. * Aceclofenac + paracetamol + Chlorzoxazone 3. * Aceclofenac + Paracetamol + Serratiopeptidase 4. * Aceclofenac + Paracetamol + Tizanidine 5. * Aceclofenac + Paracetamol + Tramadol 6. Aceclofenac + Serratiopeptidase 7. Aceclofenac + Tramadol 8. Acetaminophen + Codine phosphate 9. Acetyl Salicylic acid + Ethoheptazine 10. Choline Bitartrate + Pyndoxine + Folic Acid + Vitamin E + Cyanocobalamin + Vitamin E + Cyanocobalamin + Vitamin E + Cyanocobalamin + Chromium Nicotmate + Manganese Sulfate + Zinc Sulfate" 11. Acriflavine + Gentian violet + Brilliant green 12. * Activated charcoal + Fungal distase + Lactic acid 13. Adepalene + Methyl Paraben 14. Adenocyl Cobalamine + Carbonyl lon + Folic Acid + Zinc Ascorbate 15. Adenocyl Cobalamine + Carbonyl Iron + Folic acid 16. Alendronate sodium + Calcium Carbonate + Vit - D3 17. Alendronate sodium + Chlicalceferol f+ Calcium Citrate + Magnesium Hydroxide 18. Allantoin + Dimethicone + Metylparaben + Propylparaben 19. Allantoin + Triclosan + Vit - E + Zinc Oxide 20. Allantoin + Vit - E + Cammelina Sinensis 21. Allobarbitone + Phospho - dimethyl - isopropyl - pyrazolone 22. Aloe extract + allantocin + Alfa tocoferal acetate + D-panthemol + Vita-A 23. Aloe extract + Vit - E + Dimethicone + Glycerine 24. Aloe vera + Jojoba oil + Vit - E 25. Aloe vera + Orange oil 26. Aloe vera + Vit-e acetate 27. Aloe + tocopherol 28. Aloevera
    [Show full text]
  • RP-HPLC Method for Determination of Several Nsaids and Their Combination Drugs
    Hindawi Publishing Corporation Chromatography Research International Volume 2013, Article ID 242868, 13 pages http://dx.doi.org/10.1155/2013/242868 Research Article RP-HPLC Method for Determination of Several NSAIDs and Their Combination Drugs Prinesh N. Patel, Gananadhamu Samanthula, Vishalkumar Shrigod, Sudipkumar C. Modh, and Jainishkumar R. Chaudhari Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Balanagar, Hyderabad, Andhra Pradesh 500037, India Correspondence should be addressed to Gananadhamu Samanthula; [email protected] Received 29 June 2013; Accepted 13 October 2013 Academic Editor: Andrew Shalliker Copyright © 2013 Prinesh N. Patel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. An RP-HPLC method for simultaneous determination of 9 NSAIDs (paracetamol, salicylic acid, ibuprofen, naproxen, aceclofenac, diclofenac, ketorolac, etoricoxib, and aspirin) and their commonly prescribed combination drugs (thiocolchicoside, moxifloxacin, clopidogrel, chlorpheniramine maleate, dextromethorphan, and domperidone) was established. The separation was performed on ∘ Kromasil C18 (250 × 4.6 mm, 5 m) at 35 C using 15 mM phosphate buffer pH 3.25 and acetonitrile with gradient elution ata flow rate of 1.1 mL/min. The detection was performed by a diode array detector (DAD) at 230 nm with total run time of 30min. 2 Calibration curves were linear with correlation coefficients of determinationr ( ) > 0.999. Limit of detection (LOD) and Limit of quantification (LOQ) ranged from 0.04 to 0.97 g/mL and from 0.64 to 3.24 g/mL, respectively.
    [Show full text]
  • Strategies for Chemical Synthesis of Pyrazolone Derivatives and Their Bio-Significance
    Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2016, 8(5):969-981 ISSN : 0975-7384 CODEN(USA) : JCPRC5 Strategies for chemical synthesis of pyrazolone derivatives and their bio-significance Sanjeev Dhawan 1, Rakesh Narang 2, Gopal L. Khatik 2, Harish Kumar Chopra 3 and Surendra Kumar Nayak 2* 1Jubilant Chemsys (Jubilant Life Sciences Ltd) 1A, Sector 16A, Noida (Uttar Pradesh)-201301, India 2Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Lovely Professional University, Phagwara (Punjab)-144411, India 3Department of Chemistry, Sant Longowal Institute of Engineering & Technology (Deemed University), Longowal, Sangrur (Punjab)-148106, India _____________________________________________________________________________________________ ABSTRACT Over the last few decades, pyrazolone derivatives have been used for various biochemical applications. Some of these derivatives such as metamizole, phenazone, aminopyrine and propyphenazone, are widely used as anti- inflammatory and analgesics. Moreover, pyrazolones have been exhibited antioxidant, antibacterial, anticancer and several other biological activities. Thus, keeping in view of their importance, synthetic strategies for existing as well as novel pyrazolone derivatives have been developed and explored their biochemical utility. As versatile features of pyrozaolones have emerged, so the aim of the present paper is to put chemical synthetic schemes and biological advancements of pyrazolone derivatives together. Keywords : Pyrazolones,
    [Show full text]
  • Veterinary Kinsights
    Veterinary KINsights Fever: Pathways and Antipyretic Mechanisms INTRODUCTION Fever (pyrexia) is defined as "a state of elevated core temperature, which is often, but not necessarily part of the defensive response of multicellular organisms (hosts) to the invasion of live (microorganisms) or inanimate matter recognized as pathogenic or alien by the host."1 Pyrexia is the body's endogenous response to infectious, inflammatory, and other processes which trigger the release of cytokines and pyrogens.2 While pyrexia is something equine practitioners deal with on a weekly basis, when choosing if and how to control fever, it is worth taking a deeper look at how commonly used drugs affect the fever pathways. Daniel J. Dreyfuss, DVM, MA FEVER PATHWAYS The most commonly understood pathway leading to fever involves cyclooxygenase (COX) and prostaglandins. Transported via the bloodstream, cytokines reach the preoptic-anterior hypothalamus (POAH), binding to specific receptors on neurons and endothelial cells in the area proximal to the organum vasculosum lamina terminalis (OVLT). Pyrogens- either endogenous or exogenous- activate and upregulate phospholipase A2, promoting the release of arachidonic acid. Additionally, the cytokines upregulate cyclooxygenase (COX) which catalyzes the conversion of arachidonic acid to prostaglandin E2 (PGE2). The PGE2 can then bind to E-type prostaglandin receptors, (EP-receptors), on the hypothalamus—specifically EP-3 receptors— resulting in the neuronal signaling leading to elevation of the hypothalamic set point. The elevation of the set point in the hypothalamic thermoregulatory center initiates a chain of events resulting in both behavioral and physiological responses generating and conserving body heat.3,4 This is fever. NEWLY REVEALED PATHWAYS Two additional pathways have been uncovered relatively recently, within the last 25 years, that also contribute to the generation of fever.
    [Show full text]
  • Analgesic, Anti-Inflammatory, Antipyretic and Toxicological
    Saudi Pharmaceutical Journal (2011) 19, 115–122 King Saud University Saudi Pharmaceutical Journal www.ksu.edu.sa www.sciencedirect.com ORIGINAL ARTICLE Analgesic, anti-inflammatory, antipyretic and toxicological evaluation of some newer 3-methyl pyrazolone derivatives G. Mariappan a,*, B.P. Saha a, L. Sutharson b, Ankit Singh b, S. Garg b, L. Pandey a, Deepak Kumar a a Department of Pharmaceutical Chemistry, Himalayan Pharmacy Institute, Majhitar, Rangpo, East Sikkim 737136, India b Department of Pharmacology, Himalayan Pharmacy Institute, Majhitar, Rangpo, East Sikkim 737136, India Received 5 August 2010; accepted 7 January 2011 Available online 18 January 2011 KEYWORDS Abstract In this paper, we described the pharmacological and toxicological studies of three pyraz- Pyrazolone; olone derivatives namely PYZ1: 4-[4-N dimethylamino benzylidine]-3-methyl pyrazolin-5(4H)-one, Non-steroidal anti-inflam- PYZ2: 4-[2-chlorobenzylidine]-3-methylpyrazolin-5(4H)-one and PYZ3: 4-[benzylidine]-3-meth- matory; ylpyrazolin-5(4H)-one derivatives. Analgesic, anti-inflammatory and antipyretic studies of 3-methyl Acute and subacute toxicity; pyrazolone derivatives at 400 mg/kg, p.o. have shown significant activity as compared to control. Blood dyscrasias Amongst three pyrazolone derivatives, PYZ2 was found to be more active. Based on the result of pharmacological studies, PYZ2 was selected for toxicological studies. Acute toxicity studies revealed that methyl pyrazolone derivatives are non-toxic in rats up to 5000 mg/kg, p.o. The sub- acute toxicity study of PYZ2 showed that decrease in Hb content, RBC and WBC count. In bio- chemical analysis level of blood glucose and bilirubin reduced where as AST, ALT and alkaline phosphatase level elevated.
    [Show full text]